Tiagabine

Overview

Tiagabine, sold under the brand name Gabitril, is an anticonvulsant medication which is used in the treatment of epilepsy. It is also used off-label in the treatment of insomnia and anxiety disorders. However, off-label use is discouraged as the drug has been associated with new-onset seizures in people without epilepsy. Tiagabine is taken orally.[1–10] WP

Side effects of tiagabine include dizziness, asthenia, non-specific nervousness, muscle tremors, diarrhea, depression, and emotional lability. The drug acts as a selective GABA transporter 1 (GAT-1) blocker or GABA reuptake inhibitor, and hence acts as an indirect GABA receptor agonist, increasing GABAergic signaling in the brain. It may increase activation of both GABAA and GABAB receptors. The effects of tiagabine on sleep resemble those of GABAA receptor agonists like gaboxadol and muscimol, primarily enhancing slow wave sleep, and differ from those of GABAA receptor positive allosteric modulators like benzodiazepines and Z drugs. The drug's elimination half-life is 4.5 to 9 hours, but can be shorter in people taking enzyme-inducing anticonvulsants.[1][2][3][5][11–19] WP

Tiagabine was discovered in 1988 and was introduced for medical use in 1997. Generic formulations have become available. The drug is not a controlled substance in the United States.[4][20–23] WP

Drug class

GABA reuptake inhibitor GABA transporter 1 (GAT-1) inhibitor Anticonvulsant Hypnotic Anxiolytic WP

From the Wikipedia article's infobox.

Uses, dosage and effects

Epilepsy

Tiagabine is approved by the United States Food and Drug Administration (FDA) as an adjunctive treatment for partial seizures in epilepsy in individuals of age 12 and up. It is effective as monotherapy and combination therapy with other anticonvulsant drugs in the treatment of partial seizure.[24] WP

Insomnia

Tiagabine is used in the treatment of insomnia. Lower doses than those used in epilepsy, in the range of 2 to 16 mg, are used to treat insomnia.[5][6][7][25][26][27] WP

The drug has been found to enhance slow wave sleep (SWS) in the context of insomnia. Its effects on SWS are dose dependent, with a 2- to 4-fold increase in SWS at doses of 8 to 16 mg but mixed findings for a dose of 4 mg. Findings are mixed in terms of the influence of tiagabine on sleep onset, sleep duration, nighttime awakenings, self-reported sleep ratings, and ratings of restorative or refreshing sleep. Tiagabine has been found to decrease the cognitive impairment and high cortisol levels caused by sleep restriction, with this being related to the drug's SWS improvement. On the other hand, despite increasing SWS, tiagabine did not improve memory consolidation.[5][25][28–34] WP

The effects of tiagabine on sleep, for instance primarily increasing SWS, resemble those of gaboxadol and muscimol but are very different from those of conventional GABAA receptor positive allosteric modulators like benzodiazepines and Z drugs.[5][10][13][15][18][19][35] WP

The American Academy of Sleep Medicine's 2017 clinical practice guidelines recommended against the use of tiagabine in the treatment of insomnia due to limited effectiveness and very low quality of evidence.[6] WP

Anxiety disorders

Tiagabine may be prescribed off-label to treat certain anxiety disorders, such as panic disorder and social anxiety disorder. Tiagabine may be used alongside selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), or benzodiazepines for anxiety. The drug was ineffective for generalized anxiety disorder.[36–41] WP

Neuropathic pain

Tiagabine can be used in the treatment of neuropathic pain. It can be used alongside antidepressants, gabapentin, other anticonvulsants, or opioids for neuropathic pain.[36][42][43] WP

Available forms

Tiagabine is available in the form of 2, 4, 5, 10, 12, 15, and 16 mg oral tablets. The drug is taken 1 to 4 times per day due to its short elimination half-life. A sustained-release formulation would be advantageous but has not been developed or marketed.[1][2][3][14] WP

Risks and side effects

Contraindications

Contraindications of tiagabine include hypersensitivity (drug allergy) to tiagabine or its ingredients and severe hepatic impairment. The drug should be avoided in pregnant and nursing women.[1][3] WP

Side effects

Side effects of tiagabine are dose-related. The most common side effect of tiagabine is dizziness. Other side effects that have been observed with a rate of statistical significance relative to placebo include asthenia, somnolence, nervousness, memory impairment, tremor, headache, diarrhea, and depression. Adverse effects such as confusion, aphasia, stuttering, and paresthesia (a tingling sensation in the body's extremities, particularly the hands and fingers) may occur at higher dosages of the drug (e.g., over 8 mg/day). Tiagabine has been associated with new-onset seizures and status epilepticus in people without epilepsy in post-marketing surveillance. This may be dose-related, although it has been reported at doses of as low as 4 mg/day, and may also be related to concomitant use of other medications that lower the seizure threshold. Some of these seizures occurred around the time of dose increases. There may be an increased risk of psychosis with tiagabine treatment, although data is mixed and inconclusive. Tiagabine can also reportedly interfere with visual color perception. It has not been found to cause psychomotor, cognitive, or memory impairment. Unlike certain other GABAergic drugs like muscimol, gaboxadol, and CI-966, tiagabine has not been associated with hallucinogenic effects.[1][2][3][24][36][44–49] WP

Overdose

Tiagabine overdose can produce neurological symptoms such as lethargy, single or multiple seizures, status epilepticus, coma, confusion, agitation, tremors, dizziness, dystonias, abnormal posturing, and hallucinations, as well as respiratory depression, tachycardia, and hypertension or hypotension. Overdose may be fatal especially if the victim presents with severe respiratory depression or unresponsiveness.[1][50] WP

Interactions

Interactions

Combination of tiagabine with enzyme-inducing anticonvulsants like carbamazepine, phenytoin, primidone, and phenobarbital can decrease the elimination half-life of tiagabine to as low as 2 to 3 hours. Conversely, tiagabine does not significantly affect the hepatic metabolism of other anticonvulsants such as carbamazepine, phenytoin, and valproic acid. Other interactions have also been reviewed.[1][2][3] WP

Pharmacology

Pharmacodynamics

Tiagabine acts a selective GABA transporter 1 (GAT-1) blocker and hence as a GABA reuptake inhibitor (GRI). The GAT-1 is one of at least four distinct GABA transporters (GATs), with the GAT-1 being the predominant subtype in the brain, accounting for 85% of GATs in this part of the body, and thought to be responsible for most γ-aminobutyric acid (GABA) reuptake in synapses. The drug has more than 1,000-fold selectivity for the GAT-1 over the GABA transporter 2 (GAT-2), GABA transporter 3 (GAT-3), and betaine/GABA transporter (BGT-1; GAT-4). It also shows no significant affinity for GABA receptors or numerous other targets. In addition, it does not affect key cardiac ion channels. Through GAT-1 blockade, tiagabine increases levels of GABA, the major inhibitory neurotransmitter in the central nervous system, and consequently increases GABA receptor activation and GABAergic signaling, including of both GABAA and GABAB receptors. The drug has been found to increase GABAergic signaling in the hippocampus, globus pallidus, ventral pallidum, and substantia nigra in animals. It produces anticonvulsant, neuroprotective, hypnotic, analgesic, and anxiolytic-like effects in animals.[1][2][3][11–14][16][17][51–54] WP

In rodent drug discrimination tests, tiagabine partially substituted for muscimol and diazepam but did not substitute for gaboxadol, phenobarbitol, or zolpidem. When tiagabine was used as the training drug however, gaboxadol near-fully substituted for tiagabine. Similarly, indiplon partially substituted for tiagabine. On the other hand, zolpidem, eszopiclone, baclofen, and gabapentin all did not substitute for tiagabine. The GABAA receptor antagonist (+)-bicuculline at non-convulsant doses partially antagonized tiagabine's interoceptive effects, whereas higher doses that might more fully antagonize its cue were not assessed due to risk of convulsions. These findings suggest involvement of the GABAA receptor in the subjective effects of tiagabine, at least in rodents. Conversely, the GABAB receptor does not appear to be involved.[51][55–58] WP

Tiagabine increases benzodiazepines' affinity to cortical and limbic GABAA receptors and influences electroencephalography (EEG) measurements by increasing frontal activity and reducing posterior activity in the brain.[59][60] WP

With regard to pharmacophore, the most stable binding mode of tiagabine in the GAT-1 is that where the nipecotic acid fragment is located in the main ligand binding site, and aromatic thiophene rings are arranged within the allosteric site, which yields GAT-1 in an outward-open state. This interaction is mediated through GAT-1's sodium ion mimicry, hydrogen bonding and hydrophobic interactions.[61] WP

Tiagabine enhances the power of cortical delta (< 4 Hz) oscillations up to 1,000% relative to placebo, which may result in an EEG or MEG signature resembling non-rapid eye movement (NREM) sleep even while the person who has taken tiagabine is awake and conscious. This demonstrates that cortical delta activity and wakeful consciousness are not mutually exclusive, i.e., high amplitude delta oscillations are not always a reliable indicator of unconsciousness.[62] WP

Absorption

Tiagabine is nearly completely absorbed (>95%) and has an oral bioavailability of 90%. The time to peak levels is approximately 1 hour, with a range of 0.8 to 1.5 hours. Peak levels occur after 45 minutes in a fasted state and after 2.5 hours when taken with a high-fat meal. A high fat meal decreases peak levels by 40% but does not affect area-under-the-curve levels, indicating that it delays absorption but does not reduce the extent of absorption. Tiagabine was administered with food in clinical trials and it is recommended that it be taken with food. The pharmacokinetics of tiagabine are linear over a dose range of 2 to 24 mg. Steady-state levels are achieved after 2 days of continuous dosing and there is no accumulation with repeated administration. There have been found to be secondary peaks in circulating tiagabine levels which is suggestive of enterohepatic recycling.[1][3][63][64] WP

Distribution

Tiagabine is widely distributed through the body. Its volume of distribution is approximately 1 L/kg. The drug readily crosses the blood–brain barrier. The plasma protein binding of tiagabine is 96%, mainly to albumin and α₁-acid glycoprotein.[1][3] WP

Metabolism

The metabolism of tiagabine has not been fully characterized. In any case, it is metabolized by at least two known pathways. One is thiophene ring oxidation resulting in 5-oxotiagabine and the other is glucuronidation. 5-Oxotiagabine is said not to contribute to the pharmacodynamics of tiagabine. In-vitro studies suggest that tiagabine is metabolized primarily by the cytochrome P450 enzyme CYP3A4, although involvement of other enzymes like CYP1A2, CYP2D6, or CYP2C19 has not been excluded. Two other metabolites of tiagabine have yet to be identified.[1][3] WP

Elimination

Tiagabine is excreted about 2% unchanged. About 25% is excreted in urine and 63% is excreted in feces. The elimination half-life of tiagabine is 4.5 to 9.0 hours. The half-life of tiagabine was found to be decreased by 50 to 65% to 3.8 to 4.9 hours (range 2–5 hours) in patients whose hepatic enzymes had been induced with other anticonvulsants including carbamazepine, phenytoin, primidone, and phenobarbital. In addition, the half-life of tiagabine is extended to 11.7 to 15.9 hours in hepatic dysfunction. These settings as such may require dose adjustment.[1][3][21] WP

Research

Research

In addition to epilepsy, tiagabine was under formal clinical development for the treatment of anxiety disorders, insomnia, and neuropathic pain. However, development for all of these indications was discontinued. There have also been case reports and case series of tiagabine for treatment of bipolar disorder, though no clinical trials have been conducted. The drug has been studied for treatment of post-traumatic stress disorder (PTSD). It has been studied for treatment of aggression.[4][65–78] WP

History

History

Tiagabine was discovered at Novo in Denmark in 1988 by a team of medicinal chemists and pharmacologists under the general direction of Claus Bræstrup. The drug was co-developed with Abbott Laboratories, in a 40/60 cost sharing deal, with Abbott paying a premium for licensing the IP from the Danish company. It was approved for treatment of epilepsy in the United States in September 1997. In 2005, a bolded warning was added to the labeling of tiagabine by the United States Food and Drug Administration cautioning about association of new-onset seizures in people without epilepsy and discouraging off-label use. Tiagabine was previously subject to Risk Evaluation and Mitigation Strategies (REMS) in the United States, which was instituted in 2010. However, this requirement was eliminated in 2012. United States patents on tiagabine listed in the Orange Book expired in April 2016.[4][9][10][20][21][79][80][81] WP⚠ Wikipedia itself has flagged this text: citation needed.

Legal status

Availability

Tiagabine is available in countries throughout the world including Austria, Denmark, France, Germany, Spain, Switzerland, the United Kingdom, and the United States.[82] WP

Legal status

Tiagabine is a prescription-only medication but not an otherwise controlled substance in the United States.[23] WP

Chemistry

Formula

C20H25NO2S2 PC

CAS number

115103-54-3 PC

Molar mass (g/mol)

375.6 PC

IUPAC name (computed by PubChem)

(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid PC

SMILES

CC1=C(SC=C1)C(=CCCN2CCC[C@H](C2)C(=O)O)C3=C(C=CS3)C PC

InChIKey

PBJUNZJWGZTSKL-MRXNPFEDSA-N PC

PubChem CID

60648

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Gabitril (tiagabine hydrochloride) prescribing information
2. Journal / agency Leach JP, Brodie MJ. Drug Profile: Tiagabine. Lancet. January 1998. doi:10.1016/S0140-6736(97)05035-6 · PMID 9449883
3. Journal / agency Adkins JC, Noble S. Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs. March 1998. doi:10.2165/00003495-199855030-00013 · PMID 9530548
4. Journal / agency Tiagabine. 24 October 2021
5. Journal / agency Walsh JK. Enhancement of slow wave sleep: implications for insomnia. J Clin Sleep Med. April 2009. doi:10.5664/jcsm.5.2S.S27 · PMID 19998872 · PMC2824211
6. Journal / agency Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine. February 2017. doi:10.5664/jcsm.6470 · PMID 27998379 · PMC5263087
7. Journal / agency Abad VC, Guilleminault C. Insomnia in Elderly Patients: Recommendations for Pharmacological Management. Drugs Aging. September 2018. doi:10.1007/s40266-018-0569-8 · PMID 30058034
8. Journal / agency Schwartz TL, Nihalani N. Tiagabine in anxiety disorders. Expert Opin Pharmacother. October 2006. doi:10.1517/14656566.7.14.1977 · PMID 17020423
9. Journal / agency Navab P, Guilleminault C. Emerging pharmacotherapeutic agents for insomnia: a hypnotic panacea?. Expert Opin Pharmacother. September 2006. doi:10.1517/14656566.7.13.1731 · PMID 16925500
10. Journal / agency Ioachimescu OC, El-Solh AA. Pharmacotherapy of insomnia. Expert Opin Pharmacother. June 2012. doi:10.1517/14656566.2012.683860 · PMID 22578014
11. Journal / agency Meldrum BS, Chapman AG. Basic mechanisms of gabitril (tiagabine) and future potential developments. Epilepsia. 1999. doi:10.1111/j.1528-1157.1999.tb02087.x · PMID 10612355
12. Journal / agency Soudijn W, van Wijngaarden I. The GABA transporter and its inhibitors. Curr Med Chem. October 2000. doi:10.2174/0929867003374363 · PMID 10911018
13. Journal / agency Winsky-Sommerer R. Role of GABAA receptors in the physiology and pharmacology of sleep. Eur J Neurosci. May 2009. doi:10.1111/j.1460-9568.2009.06716.x · PMID 19473233
14. Journal / agency Brodie MJ. Tiagabine pharmacology in profile. Epilepsia. 1995. doi:10.1111/j.1528-1157.1995.tb06015.x · PMID 8595791
15. Journal / agency Bateson, Alan N. Further potential of the GABA receptor in the treatment of insomnia. Sleep Medicine. 2006. doi:10.1016/j.sleep.2006.03.001
16. Journal / agency Staner L. Sleep disturbances, psychiatric disorders, and psychotropic drugs. Dialogues Clin Neurosci. 2005. doi:10.31887/DCNS.2005.7.4/lstaner · PMID 16416708 · PMC3181742
17. Journal / agency Greene RW, Frank MG. Slow wave activity during sleep: functional and therapeutic implications. Neuroscientist. December 2010. doi:10.1177/1073858410377064 · PMID 20921564
18. Journal / agency Steiger A. Neurochemical regulation of sleep. J Psychiatr Res. October 2007. doi:10.1016/j.jpsychires.2006.04.007 · PMID 16777143
19. Journal / agency Dijk DJ. Slow-wave sleep deficiency and enhancement: implications for insomnia and its management. World J Biol Psychiatry. June 2010. doi:10.3109/15622971003637645 · PMID 20509829
20. Journal / agency Andersen KE, Braestrup C, Grønwald FC, Jørgensen AS, Nielsen EB, Sonnewald U, Sørensen PO, Suzdak PD, Knutsen LJ. The synthesis of novel GABA uptake inhibitors. 1. Elucidation of the structure-activity studies leading to the choice of (R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid (tiagabine) as an anticonvulsant drug candidate. Journal of Medicinal Chemistry. June 1993. doi:10.1021/jm00064a005 · PMID 8510100
21. Journal / agency Luer MS, Rhoney DH. Tiagabine: a novel antiepileptic drug. Ann Pharmacother. November 1998. doi:10.1345/aph.18053 · PMID 9825084
22. Other Generic Gabitril Availability & Release Date. 8 January 2026
23. Harm reduction site Erowid Tiagabine (Gabitril) Vault: Law. 10 May 2016
24. Journal / agency Tiagabine. 2012. PMID 31643697
25. Journal / agency Hall-Porter M, Walsh JK. Sleep Deprivation, Stimulant Medications, and Cognition. 23 August 2012. doi:10.1017/cbo9780511783005.018
26. Journal / agency Abad VC, Guilleminault C. Pharmacological treatment of sleep disorders and its relationship with neuroplasticity. Curr Top Behav Neurosci. 2015. doi:10.1007/7854_2014_365 · PMID 25585962
27. Journal / agency Schweitzer PK, Feren SD. Clinical Handbook of Insomnia. 2017. doi:10.1007/978-3-319-41400-3_7
28. Journal / agency Walsh JK, Zammit G, Schweitzer PK, Ondrasik J, Roth T. Tiagabine enhances slow wave sleep and sleep maintenance in primary insomnia. Sleep Med. March 2006. doi:10.1016/j.sleep.2005.05.004 · PMID 16260179
29. Journal / agency Walsh JK, Perlis M, Rosenthal M, Krystal A, Jiang J, Roth T. Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia. J Clin Sleep Med. January 2006. PMID 17557435
30. Journal / agency Walsh JK, Randazzo AC, Frankowski S, Shannon K, Schweitzer PK, Roth T. Dose-response effects of tiagabine on the sleep of older adults. Sleep. June 2005. doi:10.1093/sleep/28.6.673 · PMID 16477953
31. Journal / agency Roth T, Wright KP, Walsh J. Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, double-blind, placebo-controlled study. Sleep. March 2006. doi:10.1093/sleep/29.3.335 · PMID 16553019
32. Journal / agency Zhang Y, Gruber R. Can Slow-Wave Sleep Enhancement Improve Memory? A Review of Current Approaches and Cognitive Outcomes. Yale J Biol Med. March 2019. PMID 30923474 · PMC6430170
33. Journal / agency Walsh JK, Randazzo AC, Stone K, Eisenstein R, Feren SD, Kajy S, Dickey P, Roehrs T, Roth T, Schweitzer PK. Tiagabine is associated with sustained attention during sleep restriction: evidence for the value of slow-wave sleep enhancement?. Sleep. April 2006. PMID 16676776
34. Journal / agency Feld GB, Wilhelm I, Ma Y, Groch S, Binkofski F, Mölle M, Born J. Slow wave sleep induced by GABA agonist tiagabine fails to benefit memory consolidation. Sleep. September 2013. doi:10.5665/sleep.2954 · PMID 23997364 · PMC3738040
35. Journal / agency Mathias S, Wetter TC, Steiger A, Lancel M. The GABA uptake inhibitor tiagabine promotes slow wave sleep in normal elderly subjects. Neurobiol Aging. 2001. doi:10.1016/s0197-4580(00)00232-3 · PMID 11182474
36. Other Stahl SM. Stahl's essential psychopharmacology: the prescriber's guide; antipsychotics and mood stabilizers. 2009
37. Journal / agency Caldiroli A, Capuzzi E, Tagliabue I, Ledda L, Clerici M, Buoli M. New frontiers in the pharmacological treatment of social anxiety disorder in adults: an up-to-date comprehensive overview. Expert Opin Pharmacother. February 2023. doi:10.1080/14656566.2022.2159373 · PMID 36519357
38. Journal / agency Dunlop BW, Papp L, Garlow SJ, Weiss PS, Knight BT, Ninan PT. Tiagabine for social anxiety disorder. Hum Psychopharmacol. June 2007. doi:10.1002/hup.846 · PMID 17476705
39. Journal / agency Fagan HA, Baldwin DS. Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions. Expert Rev Neurother. June 2023. doi:10.1080/14737175.2023.2211767 · PMID 37183813
40. Journal / agency Pollack MH, Tiller J, Xie F, Trivedi MH. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol. June 2008. doi:10.1097/JCP.0b013e318172b45f · PMID 18480688
41. Journal / agency Pollack MH, Roy-Byrne PP, Van Ameringen M, Snyder H, Brown C, Ondrasik J, Rickels K. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry. November 2005. doi:10.4088/jcp.v66n1109 · PMID 16420077
42. Journal / agency Chandramouli J. Newer anticonvulsant drugs in neuropathic pain and bipolar disorder. J Pain Palliat Care Pharmacother. 2002. doi:10.1080/j354v16n04_03 · PMID 14635823
43. Journal / agency Backonja MM. Use of anticonvulsants for treatment of neuropathic pain. Neurology. September 2002. doi:10.1212/wnl.59.5_suppl_2.s14 · PMID 12221151
44. Journal / agency Leppik IE. Tiagabine: the safety landscape. Epilepsia. 1995. doi:10.1111/j.1528-1157.1995.tb06009.x · PMID 8595787
45. Other Eadie MJ, Vajda F. Antiepileptic Drugs: Pharmacology and Therapeutics. 6 December 2012
46. Other Leduc B. Foye's Principles of Medicinal Chemistry. 24 January 2012
47. Other Meyler's Side Effects of Psychiatric Drugs. 2009
48. Journal / agency Wafford KA, Ebert B. Gaboxadol--a new awakening in sleep. Curr Opin Pharmacol. February 2006. doi:10.1016/j.coph.2005.10.004 · PMID 16368265
49. Journal / agency Hollister, Leo E. New class of hallucinogens: GABA-enhancing agents. Drug Development Research. 1990. doi:10.1002/ddr.430210311
50. Journal / agency Spiller HA, Winter ML, Ryan M, Krenzelok EP, Anderson DL, Thompson M, Kumar S. Retrospective evaluation of tiagabine overdose. Clinical Toxicology. 2009. doi:10.1080/15563650500357529 · PMID 16440513
51. Journal / agency McDonald LM, Sheppard WF, Staveley SM, Sohal B, Tattersall FD, Hutson PH. Discriminative stimulus effects of tiagabine and related GABAergic drugs in rats. Psychopharmacology (Berl). May 2008. doi:10.1007/s00213-008-1077-z · PMID 18264695
52. Journal / agency Borden LA, Murali Dhar TG, Smith KE, Weinshank RL, Branchek TA, Gluchowski C. Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol. October 1994. doi:10.1016/0922-4106(94)90089-2 · PMID 7851497
53. Journal / agency Kowalska M, Fijałkowski Ł, Kubacka M, Sałat K, Grześk G, Nowaczyk J, Nowaczyk A. Antiepileptic Drug Tiagabine Does Not Directly Target Key Cardiac Ion Channels Kv11.1, Nav1.5 and Cav1.2. Molecules. June 2021. doi:10.3390/molecules26123522 · PMID 34207748 · PMC8226520
54. Journal / agency Pollack MH, Roy-Byrne PP, Van Ameringen M, Snyder H, Brown C, Ondrasik J, Rickels K. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. The Journal of Clinical Psychiatry. November 2005. doi:10.4088/JCP.v66n1109 · PMID 16420077
55. Journal / agency McDonald LM, Sheppard WF, Staveley SM, Sohal B, Tattersall FD, Hutson PH. Gaboxadol, a selective extrasynaptic GABA(A) agonist, does not generalise to other sleep-enhancing drugs: a rat drug discrimination study. Neuropharmacology. March 2007. doi:10.1016/j.neuropharm.2006.10.009 · PMID 17196996
56. Journal / agency Nielsen EB, Suzdak PD, Andersen KE, Knutsen LJ, Sonnewald U, Braestrup C. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol. April 1991. doi:10.1016/0014-2999(91)90438-v · PMID 1832636
57. Journal / agency Jones HE, Balster RL. Muscimol-like discriminative stimulus effects of GABA agonists in rats. Pharmacol Biochem Behav. February 1998. doi:10.1016/s0091-3057(97)00413-9 · PMID 9476976
58. Journal / agency Grech DM, Balster RL. Discriminative stimulus effects of presynaptic GABA agonists in pentobarbital-trained rats. Pharmacol Biochem Behav. January 1994. doi:10.1016/0091-3057(94)90104-x · PMID 8115428
59. Journal / agency Frankle WG, Cho RY, Mason NS, Chen CM, Himes M, Walker C, Lewis DA, Mathis CA, Narendran R. 11Cflumazenil binding is increased in a dose-dependent manner with tiagabine-induced elevations in GABA levels. PLOS ONE. 2012. doi:10.1371/journal.pone.0032443 · PMID 22384252 · PMC3288104
60. Journal / agency Shaw AD, Chandler HL, Hamandi K, Muthukumaraswamy SD, Hammers A, Singh KD. Tiagabine induced modulation of oscillatory connectivity and activity match PET-derived, canonical GABA-A receptor distributions. European Neuropsychopharmacology. September 2021. doi:10.1016/j.euroneuro.2021.04.005 · PMID 33957336 · PMC8415204
61. Journal / agency Łątka K, Bajda M. Analysis of Different Binding Modes for Tiagabine within the GAT-1 Transporter. Biomolecules. November 2022. doi:10.3390/biom12111663 · PMID 36359013 · PMC9687605
62. Journal / agency Frohlich J, Mediano PA, Bavato F, Gharabaghi A. Paradoxical pharmacological dissociations result from drugs that enhance delta oscillations but preserve consciousness. Communications Biology. June 2023. doi:10.1038/s42003-023-04988-8 · PMID 37340024 · PMC10282051
63. Journal / agency Gustavson LE, Mengel HB. Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia. June 1995. doi:10.1111/j.1528-1157.1995.tb02575.x · PMID 7555975
64. Journal / agency Lau AH, Gustavson LE, Sperelakis R, Lam NP, El-Shourbagy T, Qian JX, Layden T. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia. April 1997. doi:10.1111/j.1528-1157.1997.tb01734.x · PMID 9118850
65. Journal / agency Vasudev A, Macritchie K, Rao SN, Geddes J, Young AH. Tiagabine in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev. December 2011. doi:10.1002/14651858.CD005173.pub3 · PMID 22161389 · PMC12080104
66. Journal / agency Vasudev A, Macritchie K, Rao SK, Geddes J, Young AH. Tiagabine for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev. December 2012. doi:10.1002/14651858.CD004694.pub3 · PMID 23235614 · PMC7388918
67. Journal / agency Reinares M, Rosa AR, Franco C, Goikolea JM, Fountoulakis K, Siamouli M, Gonda X, Frangou S, Vieta E. A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression. Int J Neuropsychopharmacol. March 2013. doi:10.1017/S1461145712000491 · PMID 22575611
68. Journal / agency Rosa AR, Fountoulakis K, Siamouli M, Gonda X, Vieta E. Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials. CNS Neurosci Ther. June 2011. doi:10.1111/j.1755-5949.2009.00089.x · PMID 20015083 · PMC6493801
69. Journal / agency Wang HR, Woo YS, Bahk WM. Anticonvulsants to treat post-traumatic stress disorder. Hum Psychopharmacol. September 2014. doi:10.1002/hup.2425 · PMID 25131430
70. Journal / agency Berlin HA. Antiepileptic drugs for the treatment of post-traumatic stress disorder. Curr Psychiatry Rep. August 2007. doi:10.1007/s11920-007-0035-5 · PMID 17880860
71. Journal / agency Lee DJ, Schnitzlein CW, Wolf JP, Vythilingam M, Rasmusson AM, Hoge CW. PSYCHOTHERAPY VERSUS PHARMACOTHERAPY FOR POSTTRAUMATIC STRESS DISORDER: SYSTEMIC REVIEW AND META-ANALYSES TO DETERMINE FIRST-LINE TREATMENTS. Depress Anxiety. September 2016. doi:10.1002/da.22511 · PMID 27126398
72. Journal / agency Connor KM, Davidson JR, Weisler RH, Zhang W, Abraham K. Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology (Berl). January 2006. doi:10.1007/s00213-005-0265-3 · PMID 16341846
73. Journal / agency Davidson JR, Brady K, Mellman TA, Stein MB, Pollack MH. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol. February 2007. doi:10.1097/JCP.0b013e31802e5115 · PMID 17224720
74. Journal / agency Krystal AD, Zhang W, Davidson JR, Connor KM. The sleep effects of tiagabine on the first night of treatment predict post-traumatic stress disorder response at three weeks. J Psychopharmacol. May 2014. doi:10.1177/0269881113509903 · PMID 24288237
75. Journal / agency Stanford MS, Anderson NE, Lake SL, Baldridge RM. Pharmacologic treatment of impulsive aggression with antiepileptic drugs. Curr Treat Options Neurol. September 2009. doi:10.1007/s11940-009-0043-3 · PMID 19744405
76. Journal / agency Gowin JL, Green CE, Alcorn JL, Swann AC, Moeller FG, Lane SD. Chronic tiagabine administration and aggressive responding in individuals with a history of substance abuse and antisocial behavior. J Psychopharmacol. July 2012. doi:10.1177/0269881111408962 · PMID 21730016 · PMC4777893
77. Journal / agency Lieving LM, Cherek DR, Lane SD, Tcheremissine OV, Nouvion SO. Effects of acute tiagabine administration on aggressive responses of adult male parolees. J Psychopharmacol. March 2008. doi:10.1177/0269881107078489 · PMID 17715212
78. Journal / agency Hoffman DA. Tiagabine for rage, aggression, and anxiety. J Neuropsychiatry Clin Neurosci. 2005. doi:10.1176/jnp.17.2.252 · PMID 15939984
79. Journal / agency Supplement Approval
80. Journal / agency Supplement approval - Release REMS requirement
81. Journal / agency Search Results for Tiagabine
82. Other Index Nominum 2000: International Drug Directory. 2000

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.